CYRx

Cryoport is a publicly traded life sciences services company focused on temperature-controlled supply chain solutions for biopharma, cell and gene therapy, reproductive medicine, and animal health customers. Rather than developing therapeutics, the company provides mission-critical bio-logistics, biostorage, bioservices, bioprocessing support, and cryogenic equipment used across clinical and commercial workflows. Cryoport operates through a family of businesses that includes Cryoport Systems, MVE Biological Solutions, and CRYOGENE, and describes itself as a global leader in supporting the cell and gene therapy market. Its business is infrastructure- and services-oriented, enabling transport, storage, handling, and monitoring of sensitive biologic materials worldwide. For a biotech analyst, CYRX should be understood primarily as a life-science tools and services platform supporting advanced therapies rather than as a drug developer.